Table 1.
Baseline characteristics of the control and intervention group.
| Characteristics | Control groupa | Intervention group |
|---|---|---|
| Age (Mean ± SD; years) | 41.49 ± 9.33 | 41.74 ± 7.93 |
| Gender | ||
| Men n (%) | 28 (65.12) | 28 (65.12) |
| Women n (%) | 15 (34.88%) | 15 (34.88%) |
| Ethnicity n (%) | ||
| Caucasian | 31 (72.09) | 26 (60.47) |
| Mulatto | 10 (23.26) | 13 (30.23) |
| Asian | – | 1 (2.33) |
| Black | 2 (4.65) | 3 (6.98) |
| HIV diagnosis (Mean [CI]; years) | 7.05 [5.32–8.78] | 8.02 [6.06–9.98] |
| HIV treatment duration (Mean [CI]; years) | 5.98 [4.41–7.55] | 6.35 [4.70–7.99] |
| Number of comorbidities (Mean ± SD) | 2.70 ± 1.70 | 2.80 ± 1.90 |
| Number of tablets per day (Mean ± SD) | 9.55 ± 4.70 | 10.25 ± 4.21 |
| Initial CD4 mean count ([CI]; cells/mm3) | 291.09 [210.34–371.84] | 297.72 [208.30–387.14] |
| Initial viral load mean count ([CI]; copies/ml) | 19 × 103 [50–42 × 103] | 40 × 103 [6 × 103–75 × 103] |
| Most prescribed HAART n (%)b | ||
| AZT + 3TC + EFV | 7 (17.50) | 8 (20.00) |
| AZT + 3TC + LPV/r + TDF | 2 (5.00) | 7 (17.50) |
| TDF + 3TC + EFV | 8 (20.00) | 6 (15.00) |
| TDF + 3TC + LPV/r | 5 (12.50) | 6 (15.00) |
| AZT + 3TC + LPV/r | 4 (10,00) | 4 (10.00) |
| ABC + 3TC + EFV | 0 | 3 (7.50) |
| Other | 14 (35.00) | 6 (15.00) |
a
Data from three patients in the control group were not considered to HIV diagnosis, treatment time, tablets per day and comorbidities (n = 40).
b
Most prescribed HAART was related to n = 40 in control and intervention group. 3TC: lamivudine. ABC: abacavir. AZT: zidovudine. EFV: efavirenz. LPV/r: lopinavir/ritonavir. TDF: tenofovir.